دورية أكاديمية
Breakthrough Mpox Outbreak Investigation, the Delicate Balance Between Host Immune Response and Viral Immune Escape.
العنوان: | Breakthrough Mpox Outbreak Investigation, the Delicate Balance Between Host Immune Response and Viral Immune Escape. |
---|---|
المؤلفون: | Moretti M; From the Department of Internal Medicine and Infectious Diseases, Vrije Universiteit Brussel (VUB), Universitair ziekenhuis Brussel, Brussels., Meuwissen A; From the Department of Internal Medicine and Infectious Diseases, Vrije Universiteit Brussel (VUB), Universitair ziekenhuis Brussel, Brussels., Rezende AM, Zange S; Bundeswehr Institute of Microbiology, Munich, Germany., Van Nedervelde E; From the Department of Internal Medicine and Infectious Diseases, Vrije Universiteit Brussel (VUB), Universitair ziekenhuis Brussel, Brussels., de Block T; Clinical Virology Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium., Vercauteren K; Clinical Virology Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium., Demuyser T, Allard SD; From the Department of Internal Medicine and Infectious Diseases, Vrije Universiteit Brussel (VUB), Universitair ziekenhuis Brussel, Brussels. |
المصدر: | Sexually transmitted diseases [Sex Transm Dis] 2024 Jul 01; Vol. 51 (7), pp. 499-503. Date of Electronic Publication: 2024 Apr 19. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: J B Lippincott Country of Publication: United States NLM ID: 7705941 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-4521 (Electronic) Linking ISSN: 01485717 NLM ISO Abbreviation: Sex Transm Dis Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Philadelphia Pa : J B Lippincott Original Publication: Philadelphia, Lippincott. |
مواضيع طبية MeSH: | Disease Outbreaks* , Antibodies, Viral*/blood, Humans ; Male ; Adult ; Female ; Whole Genome Sequencing ; Vaccination ; Poxviridae Infections/epidemiology ; Poxviridae Infections/immunology ; Poxviridae Infections/virology ; Orthopoxvirus/immunology ; Orthopoxvirus/genetics ; Middle Aged |
مستخلص: | Background: Limited data are available on Mpox breakthrough infections. Purpose: The purpose of this study is to investigate a Mpox breakthrough outbreak in 3 vaccinated individuals. Methods: Study participants provided informed consent. Serology testing was performed in one involved individual (ID-1) using an in-house assay detecting anti-orthopoxvirus IgG. Whole genome sequencing (WGS) was carried out and compared with the reference sequence ON563414.3 ( https://www.ncbi.nlm.nih.gov/nuccore/ON563414.3/ ). Results: Three individuals vaccinated with modified vaccinia Ankara-Bavaria Nordic contracted Mpox following one sexual intercourse event. One of them (ID-1) had received only one vaccine dose, while the other two were fully vaccinated. ID-1 presented to the sexual health clinic of the Universitair Ziekenhuis Brussel with proctitis related to Mpox. Despite one vaccination, serology testing Three months post vaccine showed absence of Mpox virus (MPXV) specific antibodies in ID-1. In contrast, 2 weeks after the sexual intercourse, seroconversion occurred. Whole genome sequencing of the isolated MPXV showed, compared with the reference sequence, a total of seven single nucleotide variants with four of them indicating protein amino-acid changes. Conclusion: Incomplete MPXV vaccination as well as MPXV variants might result in breakthrough infections. Preventive measures, such as MPVX vaccination, could maintain immunity in individuals with higher risk of MPXV infection, and might lower disease severity. (Copyright © 2024 American Sexually Transmitted Diseases Association. All rights reserved.) |
References: | Moretti M, Heymans B, Yin N, et al. Diagnostic approach to monkeypox outbreak, a case-control study. Int J STD AIDS 2023; 34:338–345. Thornhill JP, Barkati S, Walmsley S, et al. Monkeypox virus infection in humans across 16 countries—April-June 2022. N Engl J Med 2022; 387:679–691. Martínez JI, Montalbán EG, Bueno SJ, et al. Monkeypox outbreak predominantly affecting men who have sex with men, Madrid, Spain, 26 April to 16 June 2022. Euro Surveill 2022; 27:2200471. WHO—News: WHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern. 2022. https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern . Accessed August 5, 2023. Earl PL, Americo JL, Wyatt LS, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004; 428:182–185. Bertran M, Andrews N, Davison C, et al. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: An observational study. Lancet Infect Dis 2023; 23:828–835. Sagy YW, Zucker R, Hammerman A, et al. Real-world effectiveness of a single dose of mpox vaccine in males. Nat Med 2023; 29:748–752. Overton ET, Stapleton J, Frank I, et al. Safety and immunogenicity of modified vaccinia ankara-bavarian nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: An open-label, controlled clinical phase II trial. Open Forum Infect Dis 2015; 2:ofv040. Berens-Riha N, De Block T, Rutgers J, et al. Severe mpox (formerly monkeypox) disease in five patients after recent vaccination with MVA-BN vaccine, Belgium, July to October 2022. Euro Surveill 2022; 27:2200894. Hazra A, Zucker J, Bell E, et al. Mpox in people with past infection or a complete vaccination course: A global case series. Lancet Infect Dis 2023; 24:57–64. Thy M, Peiffer-Smadja N, Mailhe M, et al. Breakthrough infections after postexposure vaccination against Mpox. N Engl J Med 2022; 387:2477–2479. Raccagni AR, Candela C, Mileto D, et al. Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination. J Infect 2023; 86:154–225. Sciensano, Belgian National Surveillance System. https://www.sciensano.be/ . Accessed August 5, 2023. Belgian Superior Health Council Advisory Report no. 9727. Vaccination strategy against Monkeypox – August 2022 (revision SHC 9720). https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20220907_shc_9727_monkeypox_vaccination_reviewed_vweb.pdf . Accessed August 5, 2023. De Baetselier I, Van Dijck C, Kenyon C, et al. Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium. Nat Med 2022; 28:2288–2292. Welkers M, Jonges M, Van den Ouden A. Monkeypox virus whole genome sequencing using combination of NextGenPCR and Oxford Nanopore. Protocols.io. https://www.protocols.io/private/974ACB78F83911EC998C0A58A9FEAC02?step=5 . Accessed January 21, 2024. DeHaven BC, Gupta K, Isaacs SN. The vaccinia virus A56 protein: A multifunctional transmembrane glycoprotein that anchors two secreted viral proteins. J Gen Virol 2011; 92(Pt 9):1971–1980. Lazear E, Peterson LW, Nelson CA, et al. Crystal structure of the cowpox virus-encoded NKG2D ligand OMCP. J Virol 2013; 87:840–850. Jacob T, Van den Broeke C, Favoreel HW. Viral serine/threonine protein kinases. J Virol 2011; 85:1158–1173. Kannan SR, Sachdev S, Reddy AS, et al. Mutations in the monkeypox virus replication complex: Potential contributing factors to the 2022 outbreak. J Autoimmun 2022; 133:102928. Cohn H, Bloom N, Cai GY, et al. Mpox vaccine and infection-driven human immune signatures: An immunological analysis of an observational study. Lancet Infect Dis 2023; 23:1302–1312. Jamard S, Handala L, Faussat C, et al. Resurgence of symptomatic Mpox among vaccinated patients: First clues from a new-onset local cluster. Infect Dis Now 2023; 53:104714. Gandhi M, Rutherford GW. Facial masking for Covid-19 - potential for "variolation" as we await a vaccine. N Engl J Med 2020; 383:e101. Mucker EM, Shamblin JD, Raymond JL, et al. Effect of Monkeypox virus preparation on the lethality of the intravenous Cynomolgus macaque model. Viruses 2022; 14:1741. Zaeck LM, Lamers MM, Verstrepen BE, et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat Med 2023; 29:270–278. Chitwood MH, Kwon J, Savinkina A, et al. Estimated testing, tracing, and vaccination targets for containment of the US Mpox outbreak. JAMA Netw Open 2023; 6:e2250984. |
المشرفين على المادة: | 0 (Antibodies, Viral) |
تواريخ الأحداث: | Date Created: 20240422 Date Completed: 20240617 Latest Revision: 20240618 |
رمز التحديث: | 20240619 |
DOI: | 10.1097/OLQ.0000000000001974 |
PMID: | 38647249 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!